NEW YORK (TheStreet) --aRepros Therapeuticsa surged in morning trading Thursday after the company announced its testosterone treatment showed superiority to an FDA-approved topical gel. The company reported top-line results for the first of two identical studies that compared its treatment, Androxal, with the leading FDA-approved Androgel. Androxal showed superiority in multiple assessments, specifically the two co-primary endpoints ofapercent change from baseline in average sperm concentration and percent of subjects considered to be responders. The study defines a responder as "an individual achieving a 24-hour average testosterone in the normal range with associated average sperm concentration >= 10 million/mL," according to the press release. Must Read: 50 Stocks Hedge Funds Love STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Androxal also showed superiority in secondary endpoints, includingachange in the key pituitary signaling hormones LH and FSH. The stock was up 10.21% to $20.07 at 9:59 a.m. More than 2.1 million shares had changed hands, compared to the average volume ofa258,220. RPRX data by YCharts EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE. a
Click to view a price quote on RPRX. Click to research the Drugs industry.
from Latest TSC Headlines http://ift.tt/1nIsBmO
No comments:
Post a Comment